PF-03475952
PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
PF-03475952 (0.0095-10000 ng/mL) binds potently and selectively to recombinant human and cynomolgus monkey CD44-Ig fusion proteins with EC50 values of 0.017 µg/mL and 0.015 µg/mL, respectively[1].
PF-03475952 (60 min) potently inhibits the interaction between recombinant CD44-Ig and HA with an IC50 of 0.41 µg/mL[1].
PF-03475952 (24 h) induces dose-dependent loss of cell surface CD44 from human CD14+ monocytes (IC50 = 3.3 µg/mL), human CD19+ B cells (IC50 = 2.4 µg/mL), human CD3+ T cells (IC50 = 2.6 µg/mL), and cynomolgus monkey CD3+ T cells (IC50 = 1.1 µg/mL) in whole blood[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys[1]
-
Dosage:1; 10; 100 mg/kg
-
Administration:i.v.; single dose
-
Result:Reduced CD44 expression on CD3+ lymphocytes below 50% of baseline for 218 hours at 1 mg/kg.
Reduced CD44 expression on CD3+ lymphocytes below 50% of baseline for 373 hours at 10 mg/kg.
Reduced CD44 expression on CD3+ lymphocytes below 50% of baseline for >504 hours at 100 mg/kg.
Achieved approximately 50% reduction in cell surface CD44 at serum levels of approximately 0.17 µg/mL for 1 mg/kg and 10 mg/kg dose groups.
Restored CD44 levels to baseline by day 22 (504 hours) in 1 mg/kg and 10 mg/kg dose groups.
CD44
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PF-03475952 Related Classifications
HY-P992437 Related Classifications
Powered by Bioz